Abstract
HER2-mutant breast cancers acquire secondary HER2 mutations that drive resistance to HER2 tyrosine kinase inhibitors, which can be overcome by combined inhibition of HER2 and MEK.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have